Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy

Pain

Volumn 105, Issue 1-2, 2003, Pages 71-78

  Watson, C Peter N ^a,e   Moulin, Dwight ^b   Watt Watson, Judith ^a   Gordon, Allan ^c   Eisenhoffer, John ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d PURDUE PHARMA L P   (United States)

^e NONE   (Canada)

Author keywords

Analgesia; Controlled release; Diabetic neuropathy; Neuropathic pain; Non cancer pain; Oxycodone; Quality of life

Indexed keywords

BENZATROPINE; OXYCODONE; PARACETAMOL;

ABDOMINAL PAIN; ADULT; ANTINOCICEPTION; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIAPHORESIS; DIARRHEA; DOSE CALCULATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVALUATION; FEMALE; HEADACHE; HUMAN; INSOMNIA; MALE; NAUSEA; NEUROPATHIC PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; SUSTAINED DRUG RELEASE; VERTIGO; VOMITING; XEROSTOMIA;

EID: 0141738781     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(03)00160-X     Document Type: Article

References (44)

1. American Diabetes Association and the American Academy of Neurology. Report and recommendations of the San Antonio Conference on Diabetic Neuropathy. Diabetes Care. 11:1988;592-597.
2. Arner S. Opioids and long-lasting pain conditions: 25-year perspective on mechanism-based treatment strategies. Pain Rev. 7:2000;81-96.
3. Backonja M., Beydoun A., Edwards K.R., Schwartz S.L., Fonseca V., Hes M., La Moreaux L., Garofalo E. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. J Am Med Assoc. 280:1998;1831-1836.
4. Calissi P.T., Jaber L.A. Peripheral diabetic neuropathy: current concepts in treatment. Ann Pharmacother. 29:1995;769-777.
5. Chadda V.S., Mathur M.S. Double blind study of the effects of diphenylhydantoin sodium on diabetic neuropathy. J Assoc Physicians India. 26:1978;403-406.
6. Cherny N.I., Thaler H.T., Friedlander-Klar H., Lapin J., Foley K.M., Houde R., Portenoy R.K. Opioid responsiveness of cancer pain syndromes caused by neuropathic pain or nociceptive mechanisms: a combined analysis of controlled single-dose studies. Neurology. 44:1994;857-861.
7. Clark C.M., Lee D.A. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med. 332:1995;1210-1217.
8. Collins S.L., Moore R.A., McQuay H.J., Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systemic review. J Pain Symptom Manage. 20:2000;449-458.
9. Cook R.J., Sackett D.L. The number needed to treat: a clinically useful measure of treatment effect. Br Med J. 310:1995;452-454.
10. Dellemijn P.L., van Duijn H., Vanneste J.A. Prolonged treatment with transdermal fentanyl in neuropathic pain. J Pain Symptom Manage. 16:1998;220-229.
11. Dyck P.J. Resolvable problems in diabetic neuropathy. J NIH Res. 2:1990;57-62.
12. Farrar J.T., Young J.P. Jr, LaMoreaux L., Werth J.L., Poole R.M. Clinical importance of changes in changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 94:2001;149-158.
13. Greene D., Stevens M. Diabetic peripheral neuropathy: new approaches to treatment, classification, and staging. Diabetes Spectrum. 6:1993;223-257.
14. Hagen N.A., Babul N. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer. 79:1997;1428-1437.
15. Harati Y., Gooch C., Swenson M., Edelman S., Greene D., Raskin P., Donofrio P., Cornblath D., Sachdeo R., Siu C.O., Kamin M. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 50:1998;1842-1846.
16. Hopman W.M., Towheed T., Anastassiades T., Tenenhouse A., Poliquin S., Berger C., et al. Canadian normative data for the SF-36 health survey. Multicentre Osteoporosis Study Research Group. Can Med Assoc J. 163:2000;265-271.
17. Kvinesdal B., Molin J., Frøland A., Gram L.F. Imipramine treatment in painful diabetic neuropathy. J Am Med Assoc. 251:1984;1727-1730.
18. Max M.B., Culnane M., Schafer S.C., Gracely R.H., Walther D.J., Smoller B., Dubner R. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology. 37:1987;589-596.
19. Max M.B., Kishore-Kumar R., Schafer S.C., Meister B., Gracely R.H., Smoller B., Dubner R. Efficacy of desipramine in painful diabetic neuropathy: a placebo controlled trial. Pain. 45:1991;3-9.
20. Max M.B., Lynch S.A., Muir J., Shoaf S.E., Smoller B., Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 326:1992;1250-1256.
21. McHorney C.A., Ware J.E. Jr, Lu R.J., Sherbourne C.D. The MOS 36-item Short-Form Health Survey (SF-36): III Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 32:1994;40-66.
22. McQuay H.J., Tramer M., Nye B.A., Carroll D., Wiffen P.J., Moore R.A. A systematic review of antidepressants in neuropathic pain. Pain. 68:1996;217-227.
23. Moore A., McQuay H., Gavaghan D. Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics. Pain. 66:1996;229-237.
24. Pappagallo M., Campbell J.N. Chronic opioid therapy as alternative treatment for postherpetic neuralgia. Ann Neurol. 35:(Suppl):1994;S54-S56.
25. Peloso P.M., Bellamy N., Bensen W., Thomson G.T., Harsanyi Z., Babul N., Darke A.C. Double blind randomised placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee. J Rheumatol. 27:2000;764-771.
26. Portenoy R.K., Coyle N. Controversies in the long-term management of analgesic therapy in patients with advanced cancer. J Pain Symptom Manage. 5:1990;307-319.
27. Porter J., Jick H. Addiction rare in patients treated with narcotics. N Engl J Med. 302:1980;123.
28. Rice A.S., Maton S., Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double-blind, placebo controlled study. Pain. 94:2001;215-224.
29. Roth S.H., Fleischmann R.M., Burch F.X., Dietz F., Bockow B., Rapoport R.J., Rutstein J., Lacouture P.G. Around-the clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med. 160:2000;853-860.
30. Rowbotham M.C., Reisner-Keller L.A., Fields H.L. Both intravenous lidocaine and morphine reduce pain of postherpetic neuralgia. Neurology. 41:1991;102-128.
31. Rowbotham M., Harden N., Stacey B., Berstein P., Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. J Am Med Assoc. 280:1998;1837-1842.
32. Rull J.A., Quibrera R., Gonzalez-Millan H., Lozano Castaneda O. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double-blind crossover trial. Diabetologia. 5:1969;215-218.
33. Saudek C.D., Werns S., Reidenberg M.M. Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clin Pharmacol Ther. 22:1977;196-199.
34. Schulz K.F. The landscape and lexicon of blinding in randomized trials. American College of Physicians-American Society of Internal Medicine. Ann Intern Med. 136:(3):2002;254-259.
35. Sindrup S.H., Jensen T.S. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 83:1999;389-400.
36. Sindrup S.H., Ejlertsen B., Frøland A., Sindrup E.H., Brosen K., Gram L.F. Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve function. Eur J Clin Pharmacol. 37:1989;151-153.
37. Sindrup S.H., Anderson G., Madsen C., Smith T., Brasen K., Jensen T.S. Tramadol relieves pain and allodynia in polyneuropathy: a randomized, double-blind controlled trial. Pain. 83:1999;85-90.
38. Tait R.C., Pollard C.A., Margolis R.B., Duckro P.N., Krause S.J. The Pain Disability Index: psychometric and validity data. Arch Phys Med Rehabil. 68:1987;438-441.
39. Vinik A., Holland M.T., Le Beau J.M., Liuzzi F.J., Stansberry K.B., Colen L.B. Diabetic neuropathies. Diabetes Care. 15:1992;1926-1975.
40. Watson C.P., Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology. 50:1998;1837-1841.
41. Watson C.P., Watt-Watson J.H. Treatment of neuropathic pain: focus on antidepressants, opioids and gabapentin. Pain Res Manag. 4:1999;168-178.
42. Watson C.P.N., Moulin D., Gordon A., Watt-Watson J., Eisenhoffer J., Quigley P., Harsany Z., Darke A. A randomised, double-blind, crossover comparison of the efficacy and safety of oral controlled-release oxycodone and active placebo in patients with painful diabetic neuropathy [abstract]. Pain. 2:(Suppl 1):2001;43.
43. Wilton T.D. Tegretol in the treatment of diabetic neuropathy. S Afr Med J. 48:1974;869-872.
44. Young R.J., Ewing D.J., Clarke B.F. Chronic and remitting painful diabetic polyneuropathy: correlations with clinical features and subsequent changes in neurophysiology. Diabetes Care. 11:1988;34-40.